At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating the treatment …

Patients who may benefit can include patients with: *Hyperphosphatemia *corrected calcium below target levels or symptomatic hypocalcemia *Hypercalcuria or nephrolithiasis despite …

Dec 19, 2024 · Reflecting this commitment, Ascendis has established a dedicated YORVIPATH team within the U.S. Ascendis Signature Access Program ® to support the patient treatment …

Feb 13, 2025 · Is Yorvipath Right for Me? Your health care provider may consider treatment with Yorvipath if you have hypoparathyroidism and have been taking calcium and vitamin D treatment.

Aug 14, 2024 · The company, through its U.S. Ascendis Signature Access Program, plans to offer patient services such as support for navigating treatment and financial assistance for eligible …

The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for YORVIPATH and any potential adverse effects on the breastfed …

Yorvipath® is a parathyroid hormone analog (PTH(1-34)) indicated for the treatment of hypoparathyroidism in adults. Conventional therapy for hypoparathyroidism consists of active …

Aug 12, 2024 · At launch, Ascendis plans to offer a suite of patient services for YORVIPATH through its U.S. Ascendis Signature Access Program (A.S.A.P.), including support navigating …

To support patients and healthcare providers, Ascendis has introduced the Yorvipath team within its U.S. Ascendis Signature Access Program. This initiative provides resources such as clinical …

Aug 15, 2024 · Upon launching YORVIPATH, Ascendis Pharma plans to introduce a comprehensive patient support initiative through its US Ascendis Signature Access Program. …